The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era

Zarnie Lwin¹, Jonathan W. Riess², David Gandara²

¹Royal Brisbane and Women’s Hospital, Brisbane, Australia; ²University of California Davis Cancer Center, Sacramento, California, USA

ABSTRACT

Despite remarkable advances in the targeted treatment of advanced non-small cell lung cancer (NSCLC) over the past several years, chemotherapy remains of paramount importance in the treatment of advanced NSCLC. Customizing treatment based on histology and molecular typing has become a standard of care in this era of targeted therapy. While new chemotherapeutic agents have proven effective, the pivotal role of platinum-based chemotherapy doublets has been confirmed. Maintenance chemotherapy has become an option, but who to employ it in remains unclear in the real-world setting. Efforts to overcome resistance to targeted agents are ongoing utilizing combination regimens of chemotherapy plus targeted agents, but optimizing combination strategies needs further exploration. This review highlights recent developments in novel chemotherapeutics and in chemotherapy strategies over the past two years. Despite advances in molecular medicine, there remains an essential role for chemotherapy in advanced NSCLC, even in the recent targeted therapy era.

KEY WORDS

Advanced non-small cell lung cancer (NSCLC); recent developments; chemotherapy strategies; targeted therapy
attempt to preserve efficacy and minimize toxicity, platinum-free combinations of newer agents have been tested against conventional platinum-based combinations. Although a recent meta-analysis of 16 randomized trials found that the efficacy was comparable between non-platinum doublets of third-generation agents and platinum-based doublets for pooled overall survival (HR =1.03, 95% CI: 0.98-1.08, P=0.290) (3), all evidence based guidelines support platinum-based therapy as standard of care. Subgroup analyses by different non-platinum doublet protocols revealed that none of the four non-platinum doublets achieved a different survival when compared with platinum-based doublets. The pooled progression-free survival showed that platinum-based doublets may have an advantage over non-platinum doublets (HR =1.06, 95% CI: 1.01-1.12, P=0.03). In this study, a meta-analysis of toxicity could not be performed.

In an attempt to show that platinum compounds were non-essential, a recent Phase III trial in advanced stage NSCLC with performance status 2 randomized patients to receive pemetrexed with or without carboplatin. All efficacy parameters favored the carboplatin-pemetrexed combination over pemetrexed alone: response rate 23.8% vs. 10.3%, PFS 5.8 vs. 2.8 months, and OS 9.3 vs. 5.3 months (4). Clearly, the weight of evidence in all categories of advanced NSCLC without EGFR mutation or ALK fusion favors platinum-based doublet therapy.

**Biomarkers to select platinum and non-platinum chemotherapy**

Utilizing DNA repair enzymes as biomarkers for better selecting front-line chemotherapy is an area of active investigation. Low ERCC1 expression by either IHC or RT-PCR has been shown in preliminary studies to be a potential biomarker of benefit to platinum compounds and low RRM1 a potential biomarker of benefit to gemcitabine. The ERCC1 enzyme removes platinum-induced DNA adducts, and thus low ERCC1 levels are associated with platinum sensitivity (5). RRM1 is a subunit of ribonucleotide reductase which is the main target of gemcitabine; thus, low RRM1 levels are associated with gemcitabine sensitivity (6). In the recently published phase III TASTE trial in metastatic NSCLC, patients were randomly assigned 2:1 to the experimental arms: (I) gemcitabine/carboplatin if RRM1 and ERCC1 were low; (II) docetaxel/carboplatin if RRM1 was high and ERCC1 was low; (III) gemcitabine/docetaxel if RRM1 was low and ERCC1 was high; and (IV) docetaxel/vinorelbine if both were high (7). Control arm patients received gemcitabine/carboplatin. There were no statistical differences for progression-free survival or overall survival. The authors note they required real-time processing of tumor specimens for ERCC1, RRM1 and in situ protein levels. Therefore day-to-day variations in the reagent assay reliability and processing procedures may have affected the reliability and reproducibility of these assays. A recent attempt to validate ERCC1 by IHC as a prognostic marker to platinum based chemotherapy in the adjuvant setting failed as the same antibody to ERCC1 (but a different batch) could not detect the functional ERCC1 isoform (8).

Thymidylate synthase (TS), the de novo source of thymidylate synthesis, is an essential enzyme for DNA replication and cell growth and one of the primary targets of pemetrexed. Pemetrexed has a potential histology-specific benefit which may be related to higher levels of TS expression in squamous histology of the lung compared to adenocarcinoma with overexpression of TS is related to a reduced sensitivity to pemetrexed (9). *In vitro* studies have correlated differential expression of TS and pemetrexed sensitivity (10). In an analysis of the largest data set for gene expression of biomarkers reported to date, significant histology-related associations for ERCC1, RRM1, and TS were seen, warranting randomized phase III trials assessing the predictive value of these chemotherapy-related biomarkers (11).

Another biomarker that may assist in chemotherapy selection is SPARC (secreted protein acidic and rich in cysteine), a matricellular glycoprotein that is produced by tumor and/or neighboring stroma. SPARC expression is thought to facilitate the intracellular accumulation of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) (12). Multiple issues in assay development, standardization, tissue processing and antibody reliability have affected the potential utility of these biomarkers to better select rationale chemotherapy combinations in advanced NSCLC. Further development of these predictive biomarkers is of interest to convert chemotherapy into targeted chemotherapy.

**Pemetrexed first line therapy for non-squamous histology**

Pemetrexed is a multi-targeted anti-folate employed: with platinum derivates for first-line treatment, as single agent for subsequent lines of treatment, and as maintenance therapy. In the landmark JMDB trial, Scagliotti et al. demonstrated no difference in overall survival between cisplatin/gemcitabine and cisplatin/pemetrexed as first-line treatment of patients with metastatic NSCLC. However, in a preplanned subset analysis the cisplatin-pemetrexed combination was superior in non-squamous histology with a median overall survival of 12.6 months in the cisplatin-pemetrexed arm and 10.9 months in the cisplatin-gemcitabine arm (HR =0.84; 95% CI: 0.71-0.99; P=0.03) (13). By contrast, patients with squamous carcinoma had a worse median overall survival in the cisplatin-pemetrexed arm than in the cisplatin-gemcitabine arm (9.4 vs. 10.8 months; HR =1.23; 95% CI: 1.0-1.5; P=0.05).

In a more recent study the Norwegian Lung Cancer Study Group enrolled 436 patients to compare health-related quality of
life (HRQoL) between carboplatin-pemetrexed and carboplatin-gemcitabine as first-line treatments for advanced NSCLC. The two regimens achieved similar results in terms of HRQoL and overall survival (7.3 months for carboplatin-pemetrexed vs. 7.0 months for carboplatin-gemcitabine; P=0.63) (14). Multivariate analyses and interaction tests did not reveal any significant associations between specific histology and survival. Carboplatin-pemetrexed combination was not superior in non-squamous histology, in contrast to the JMDB trial. In another randomized phase III trial carboplatin-pemetrexed achieved a longer median survival without toxicity when compared to carboplatin-docetaxel in advanced non-squamous NSCLC (3.2 vs. 0.7 months; HR =0.45; 95% CI: 0.34-0.61). The primary endpoint of survival without toxicity was defined as the interval from randomization to the first treatment-induced grade 3-4 adverse event (15). In a meta-analysis published in 2012, Li and colleagues evaluated a selection of clinical trials in which platinum-based combinations including pemetrexed were compared with platinum-based combinations including other third-generation agents for first-line treatment. A consistent survival advantage with pemetrexed was observed especially in non-squamous NSCLC (which represented the majority of the patients) (16). A meta-analysis of five trials (three first-line trials, one second-line trial, one maintenance trial) confirmed that pemetrexed, when compared with alternative treatments or placebo, is consistently associated with a significant overall survival improvement in non-squamous histology (HR =0.82) but not in squamous histology (HR =1.19) (17).

**Combining chemotherapy with targeted agents**

The diagnosis and management paradigm of metastatic NSCLC has transitioned into an algorithm of presence or absence of oncogene addiction as a key branch point to selecting appropriate treatment. As described above, with the identification of driver mutations such as EGFR and ALK, EGFR-TKIs and crizotinib are supplanting traditional chemotherapy for upfront treatment of these patients (18). However, initial TKI responders inevitably relapse due to acquired resistance. More recently, an added layer of complexity related to intrapatient tumor heterogeneity has been observed, particularly relevant to the clonal evolution of somatic mutations from the primary tumor to metastatic lesions and the mixed response to treatment in different tumor sites (2). At the same time, chemotherapy combinations have reached a therapeutic plateau for metastatic disease (19). Therefore, an area of focus has therefore been on interrogating the combination of novel targeted agents together with chemotherapy to optimize efficacy, survival and overcome acquired resistance. Early studies done combining EGFR-inhibitors with concurrent chemotherapy in unselected populations did not confer a survival advantage (20).

Given the lack of benefit seen in combining concurrent chemotherapy and EGFR TKIs in an unselected patient population, efforts to best integrate chemotherapy and TKI regimens are ongoing. One such approach is intercalating a TKI with chemotherapy based on the preclinical rationale that EGFR TKIs cause G1 cell-cycle arrest thus inhibiting cell-cycle dependent cytotoxic effects of chemotherapy (21). Because the mechanism of action of EGFR-TKIs has the theoretical potential to interfere with or even negate the effects of chemotherapy, it has been hypothesized that sequential or intermittent schedules to confer pharmacodynamic separation may confer better benefit (18).

Table 1 lists recent phase III trial results combining chemotherapy with a targeted agent or novel small molecule inhibitors for within the past two years. The treatment algorithms include single-target agents, multi-target agents, concurrently, intercalated with chemotherapy and as maintenance.

The recently published FASTACT-2 study shows that intercalating erlotinib and chemotherapy yields improved progression-free survival and overall survival in East Asian patients enriched for EGFR-activating mutations. However, progression-free survival and overall survival were not significantly different in EGFR wild-types groups (22). Treatment benefit was noted only in patients whose tumors harbored an EGFR activating mutation (median progression-free survival 16.8 vs. 6.9 months, HR =0.25; P<0.0001; median overall survival 31.4 vs. 20.6 months, HR =0.48; P=0.0092).

The anti-VEGF monoclonal antibody Bevacizumab has a demonstrated overall survival benefit in combination with carboplatin and paclitaxel in a phase III trial and this combination can be considered an option in treating nonsquamous NSCLC. However, since the year 2000, over 11 other phase III trials have been negative to date for an overall survival benefit when combining bevacizumab or other anti-angiogenic agents to platinum based chemotherapies. One important issue in employing anti-angiogenesis therapy is absence of a predictive marker for therapeutic benefit. Differences in progression-free survival vs. overall survival benefits may also be confounded by effect of further therapies, given the existence of a variety of moderately active agents now available for second and third line treatments.

In the recent PRONOUNCE study the primary objective was to compare progression-free survival without Grade 4 toxicity (G4PFS) between a two drug regimen (Pem/Carbo) vs. three (Pac/Carbo + Bev) in a phase III superiority trial (24). The rationale for this trial design can be questioned. Nevertheless, study outcomes were negative. In the PointBreak trial patients were randomized to carboplatin/paclitaxel/bevacizumab followed by bevacizumab maintenance and compared to carboplatin/pemetrexed/bevacizumab followed by pemetrexed/bevacizumab maintenance (25). There was no overall survival
Table 1. Recent Phase III Trials combining chemotherapy and targeted agents in the past two years.

<table>
<thead>
<tr>
<th>Targeted agent</th>
<th>Trial design and chemo partner</th>
<th>Sequencing of targeted agent</th>
<th>N</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EGFR inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erlotinib FAST-ACT2 (22)</td>
<td>First line, unselected platinum/gemcitabine + erlotinib or placebo on days 15-28 f/by erlotinib or placebo</td>
<td>Intercalated + maintenance</td>
<td>451</td>
<td>PFS = 7.6 vs. 6.0 months, HR = 0.57 (0.47-0.69) P &lt; 0.0001; OS = 18.3 vs. 15.2 months, HR = 0.79 (0.64-0.99) P = 0.0420; intercalated erlotinib vs. placebo</td>
</tr>
<tr>
<td>Cetuximab SELECT (23)</td>
<td>Second line, squamous Pem/cetux vs. Pem vs. docetaxel/cetux vs. docetaxel f/by cetux in cetux arms</td>
<td>Concurrent + maintenance</td>
<td>Pem = 605; Docetaxel = 333</td>
<td>PFS = 2.70 vs. 2.27 months, HR = 0.93 (0.81-1.08) P = 0.305; OS = 6.7 vs. 7.85 months HR 1.05, (0.91-1.2) P = 0.47; cetux + chemo vs. chemo</td>
</tr>
<tr>
<td><strong>VEGF Bevacizumab</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRONOUNCE (24)</td>
<td>First line, non squamous PemC vs. PCB f/by Pem (PemC Arm) or Bev (PCBArm)</td>
<td>Concurrent + maintenance</td>
<td>361</td>
<td>PFS = 4.4 vs. 5.5 months, HR = 1.06 (0.84-1.25) P = 0.610; OS = 10.5 vs. 11.7 months HR = 1.07 (0.83-1.36) P = 0.616; PemC vs. PCB</td>
</tr>
<tr>
<td>Bevacizumab PointBreak (25)</td>
<td>First line, non squamous PemCB f/by Pem+Bev vs. PCB f/by Bev</td>
<td>Concurrent + maintenance</td>
<td>939</td>
<td>PFS = 5.5 vs. 5.5 months, HR = 1.22 (0.71-1.98) P = 0.37; OS = 12.2 vs. 12.1 months, HR = 0.95 (0.69-1.30) P = 0.74; CED vs. placebo</td>
</tr>
<tr>
<td>Cediranib NCIC BR29 (26)</td>
<td>First line, unselected Carbo/taxol + CED or placebo f/by CED or Bev</td>
<td>Concurrent + maintenance</td>
<td>306</td>
<td>PFS = 6.0 vs. 5.5 months, HR = 0.98 (0.83-1.16) P = 0.40; sorafenib vs. placebo</td>
</tr>
<tr>
<td>Sorafenib NExUS (27)</td>
<td>First line, Non squamous cis/gem plus sorafenib or placebo f/by sorafenib or placebo</td>
<td>Concurrent + maintenance</td>
<td>772</td>
<td>PFS = 5.2 vs. 4.1 months, HR = 0.82 (0.72-0.94) P = 0.820; OS = 10.1 vs. 10.4 months, HR = 1.01 (0.87-1.17) P = 0.9; aflibercept vs. placebo</td>
</tr>
<tr>
<td>Aflibercept VITAL (28)</td>
<td>Second line, non-squamous Docetaxel + Aflibercept or placebo</td>
<td>Concurrent</td>
<td>913</td>
<td>PFS = 4.4 vs. 3.6 months, HR = 0.83 (0.7-0.99) P = 0.04; OS = No difference in OS, HR = 1.03; nintedanib vs. placebo</td>
</tr>
<tr>
<td><strong>Multitargeted agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nintedanib (VEGFR, FGFR,PDGFR inhibitor)</td>
<td>Second line, non-squamous PEM + Nintedanib or Placebo</td>
<td>Concurrent</td>
<td>713</td>
<td>PFS = 3.4 vs. 2.7 months, HR = 0.79 (0.68-0.92) P = 0.019; OS in all pts 10.1 vs. 9.1 months HR = 0.94 P = 0.272; nintedanib vs. placebo</td>
</tr>
<tr>
<td>Nintedanib LUME-lung1 (30)</td>
<td>Second line Docetaxel + Nintedanib or Placebo</td>
<td>Concurrent</td>
<td>1,314</td>
<td>PFS = 17.6 vs. 11.9 weeks, HR = 0.86 (0.69 to 1.06) P = 0.08; OS = 10.5 vs. 9.2 months, HR = 0.86 (0.65-1.13) P = 0.219; vandetanib vs. placebo</td>
</tr>
<tr>
<td>Vandetanib (31) (VEG, EGFR inhibitor)</td>
<td>Second line PEM + Vandetanib or Placebo</td>
<td>Concurrent</td>
<td>534</td>
<td></td>
</tr>
</tbody>
</table>

Pem/cetux, Pemetrexed/cetuximab; Pem, Pemetrexed; docetaxel/cetux, docetaxel/cetuximab; PemCB, Pem/Carbo/Bev; CED, Cediranib; PCB, Paclitaxel/Carboplatin/Bevacizumab; PemC, Pemetrexed/Carboplatin; Carbo/taxol, Carboplatin/paclitaxel.
Maintenance therapy strategies that improve patient outcomes are an area of active investigation in NSCLC. Both continuation and switch maintenance approaches have been actively studied. Continuation maintenance strategies hope to suppress tumor growth beyond the time of 4 cycles of standard front-line chemotherapy. Alternatively, switch maintenance strategies hope to delay resistance to treatment by incorporating a new chemotherapeutic agent with a different mechanism of action. Ultimately, the goal of maintenance therapy is not just enhance progression-free survival, but to prolong overall survival without decreasing QoL.

The most prominent recently published study of maintenance chemotherapy is PARAMOUNT. In this large, phase III trial patients with non-squamous NSCLC were randomized to pemetrexed or placebo plus best supportive care after induction with 4 cycles of cisplatin/pemetrexed. Both progression-free (HR =0.62, P=0.0001) and overall survival (HR =0.78, P=0.019) were significantly prolonged with continuation maintenance pemetrexed (35,36). Discontinuation of maintenance pemetrexed due to toxicity was low (5%). A comparable number of patients in both treatment arms received post-discontinuation therapy (64% of patients treated with placebo and 58% of patients treated with pemetrexed maintenance). However, maintenance therapy is expensive. A recent Chinese cost-effectiveness analysis estimated cost per quality adjusted life year of maintenance pemetrexed in the Chinese health care system to be between $125,000 and $180,000 (37). Furthermore, it remains unclear in non-squamous patients whether close follow up with timely second line therapy or re-initiation of pemetrexed upon progression would have comparable efficacy to pemetrexed maintenance, particularly in patients who initially benefit from a first-line platinum/ pemetrexed doublet, and then are observed without maintenance. Lastly, there is considerable debate as to whether 4 cycles of induction chemotherapy is an adequate point for consideration of maintenance, or whether the 2 months increase in median PFS could be achieved with further induction therapy.

In another pemetrexed maintenance trial (JMEN) that used a switch maintenance strategy, overall survival was improved and patients’ QoL was similar compared to placebo except for a slight decrease in appetite and delayed worsening of hemoptysis and pain (38). In particular, the results of this trial are confounded by a very low rate of second line crossover to pemetrexed in the placebo arm, making real world interpretation difficult. Other trials employing maintenance with gemcitabine and docetaxel after frontline chemotherapy did not show any overall survival benefit when compared to initiating treatment after progression of disease (39,40). A criticism of many maintenance trials is the high percentage of patients randomized to the best-supportive care only arm failing to receive second-line therapy upon progression. Subset analyses of some maintenance treatment trials suggest that patients with stable disease may benefit more from a maintenance strategy, rather than those who respond. Though hypothesis generating, the rationale is sound: patients who do not have a response may progress quicker and would typically receive early second line agents. Thus, regardless of terminology, a switch to docetaxel or gemcitabine could be considered second line therapy instead of maintenance therapy, particularly in squamous histology patients with good functional status who do not have a response to frontline therapy.

New chemotherapeutics

Albumin-bound paclitaxel

Taxanes have been a backbone of NSCLC therapy for well over a decade. 130-nm albumin bound paclitaxel (nab-paclitaxel) differs from standard bound paclitaxel (sb-paclitaxel) by being preferentially taken up into cancer cells via caveolae mediated transcytosis. The proposed mechanism involves enhanced drug delivery to tumor by albumin binding to SPARC (secreted protein, acidic and rich in cysteine), which is preferentially expressed on tumor cells compared to normal tissue (41). It also lacks the cremophor vehicle present in standard bound paclitaxel that can trigger allergic reactions. Nab-paclitaxel was studied in combination with carboplatin and compared to sb-paclitaxel plus carboplatin as first-line therapy of metastatic NSCLC in a large, randomized phase III trial. This trial met its primary endpoint of increased response rate for the carboplatin and nab-paclitaxel combination (33% vs. 25%, P=0.005) (42). The largest gains in response rates were noted in squamous cell histology patients (41% vs. 24%) and no increase in ORR was seen in non-squamous histology. There also was less grade ≥3 neuropathy compared to the sb-paclitaxel combination. However, no significant improvement in overall or progression free survival was noted. In a subset analysis, patients from North America and age ≥70 had significantly improved overall survival with nab-
paclitaxel, however this subset analysis should be considered hypothesis generating only. Nab-paclitaxel is clearly a suitable substitute for sb-paclitaxel when allergy to the cremophor vehicle is present or in patients with baseline neuropathy. In addition, nab-paclitaxel could be considered preferential in those with squamous histology when a response is needed, where a subset analysis showed a higher difference in response rates. This rationale is also supported by the realization that new treatment options for NSCLC patients with squamous histology lag far behind those for lung adenocarcinoma.

**Cabazitaxel**

Cabazitaxel is another taxane currently being studied in a phase II trial in advanced NSCLC (NCT01438307). Recent data in metastatic prostate cancer that showed a significant overall survival benefit underlies the merit of its evaluation in NSCLC (43). Trial results with cabazitaxel in metastatic NSCLC are not yet mature.

**Vintafolide (EC145): a folate-vinca alkaloid conjugate**

Vinca alkaloids have documented activity in NSCLC, but have largely been supplanted by taxanes and pemetrexed for first or second line systemic treatment of NSCLC. Vintafolide is a conjugate folate molecule linked to vinblastine. Over 75% of NSCLC is folate receptor positive (by immunohistochemistry), offering the potential of folate receptor-targeted therapy. In a recent phase II trial, companion imaging of the folate receptor via 99mTc-EC20 CT scans was used to select patients with folate receptor expressing tumors for treatment with vintafolide. Thus, EC20 uptake is under development as a potential predictive biomarker to vintafolide. In a phase II trial of heavily pretreated relapsed/refractory NSCLC patients with positive EC20 scans, clinical benefit (stable disease + overall response rate) was seen in 26% of patients (44). Currently vintafolide is being studied in combination with docetaxel in a randomized phase II trial of relapsed/refractory NSCLC patients (NCT01577654).

**Eribulin mesylate**

Eribulin mesylate is a synthetic analogue of halichondron B isolated from a rare marine sponge. It inhibits microtubule dynamics using a distinct mechanism from taxanes or vinca alkaloids. It was recently approved for breast cancer based on a randomized phase II trial in NSCLC patients who previously received an anthracycline and a taxane (45). In a phase II trial in NSCLC patients who had previously received a taxane, response rates were low (5%), but 50% of patients achieved stable disease (46). Eribulin is currently being studied in combination with erlotinib (NCT01104155), pemetrexed (NCT01126736) or physicians choice of control drug (NCT01454934) in 3 separate clinical trials.

**Ixabepilone**

Ixabepilone is an epithilone (a novel anti-microtubule class of agent) that similar to taxanes binds and stabilizes microtubules, eventually resulting in G2/M cell-cycle arrest. Some preclinical studies show it is active in taxane-resistant models and ixabepilone is approved for treatment of metastatic breast cancer. In a randomized phase II trial in NSCLC, it did not improve overall survival or achieve any other clinically meaningful endpoint (47). The investigators stratified patients based on beta-3 tubulin immunohistochemistry and showed it to be a negative prognostic indicator, but not a predictive marker of benefit to ixabepilone. As there is no clear signal of superiority compared to paclitaxel, the future development of ixabepilone in advanced NSCLC treatment is unclear.

**Pralatrexate**

Pralatrexate, a folate analogue targeting dihydrofolate reductase, was recently studied in a randomized phase II trial compared to erlotinib in metastatic NSCLC patients who progressed on first-line therapy. A trend towards increased overall survival was observed and an increase in progression free survival was noted (48). In this study 18 of 100 patients treated with pralatrexate had prior pemetrexed. There was a high rate of mucositis with pralatrexate despite B12 and folic acid supplementation. As pemetrexed is increasingly being incorporated into upfront treatment regimens of non-squamous NSCLC and the toxicity of pralatrexate appears higher, the role of additional anti-folate therapies is unclear.

**Summary of new chemotherapeutic agents**

Multiple new chemotherapeutic agents are currently in clinical development or have been recently evaluated in NSCLC (Table 2). Several of these drugs are from similar drug classes to those already shown to be active in NSCLC (cabazitaxel, pralatrexate) while others have been reformulated to preferentially target tumor cells (albumin-bound paclitaxel, vintafolide). Ixabepilone and eribulin affect microtubule dynamics through distinct mechanisms of action compared to taxanes. None of the clinical trials to date with these drugs suggest dramatic benefits in advanced NSCLC patients, but some of these new agents may have a role in specific treatment settings, as per nab-paclitaxel discussed above.

**Discussion**

Chemotherapy remains the indispensible choice for the vast
majority of patients with advanced NSCLC, given the relative rarity of currently defined and treatable oncogene-driven patient subsets. Several new chemotherapeutic agents for NSCLC are in clinical development, though their actual role in the current treatment paradigm is yet to be determined. As we seek to rank, order and rationally combine existing chemotherapies to achieve optimal patient outcomes, some promising results have emerged. Switch or continuation maintenance strategies are of benefit, but defining exactly who to treat remains problematic, as the trial designs may not have always reflected real-world considerations. Several aspects of maintenance therapy need further examination including the optimal number of induction chemotherapy cycles, the role of treatment-free intervals, QoL, economic considerations, and whether progression-free survival is a worthy therapeutic goal in this disease setting (49). Platinum based cytotoxic chemotherapy has been the backbone of treatment for metastatic NSCLC for decades and non-platinum combinations have not shown superiority. Attempts to employ biomarkers of DNA repair or other biomarkers for chemotherapy have been hindered by methodological issues to date. Optimal strategies for integrating chemotherapy and targeted therapeutics are an area of active investigation with promising results.

Despite the remarkable advances in the targeted treatment of NSCLC in the past several years, chemotherapy remains of paramount importance in the treatment of advanced NSCLC.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References


Table 2. Newly studied chemotherapeutics in metastatic NSCLC.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Trial design</th>
<th>Clinical setting</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nab-paclitaxel</td>
<td>Randomized, phase III (with carboplatin)</td>
<td>1st line</td>
<td>ORR 33% vs. 25% (P=0.005);</td>
</tr>
<tr>
<td></td>
<td>compared to carboplatin sb-paclitaxel</td>
<td></td>
<td>median PFS 6.3 vs. 5.8 mo. (P=0.214);</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>median OS 12.1 vs. 11.2 (P=0.27)</td>
</tr>
<tr>
<td>Vintafolide</td>
<td>Phase II, relapsed/refractory NSCLC with companion EC20 Scans</td>
<td>Beyond 2nd line</td>
<td>Clinical benefit (CB) = 31%;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CB in patients with EC20+ imaging 50%</td>
</tr>
<tr>
<td>Eribulin</td>
<td>Single agent phase II</td>
<td>2nd and 3rd line</td>
<td>ORR = 5%; SD = 24%</td>
</tr>
<tr>
<td>Ixabepilone</td>
<td>Randomized, phase II (with carboplatin) vs.</td>
<td>1st Line</td>
<td>PFS; HR 1.04 (0.78-1.41)</td>
</tr>
<tr>
<td></td>
<td>carboplatin/ixabepilone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pralatrexate</td>
<td>Randomized, phase II (compared to erlotinib)</td>
<td>2nd and 3rd line</td>
<td>OS HR 0.84 (95% CI: 0.61-1.14);</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-sq NSCLC; OS HR 0.65 (0.42-1.0)</td>
</tr>
</tbody>
</table>


23. Kim ES, Neubauer MA, Cohn AL, et al. SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy. J Clin Oncol 2012;30:abstr 7502.


